Navigation Links
Reportlinker Adds Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Date:3/14/2011

NEW YORK, March 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0453472/Methicillin-Resistant-Staphylococcus-Aureus-MRSA-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html

Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

SummaryGlobalData, the industry analysis specialist, has released its new report, "Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global MRSA market. The report identifies the key trends shaping and driving the global MRSA market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global MRSA sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The global MRSA market was valued at $900m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.8% for the next seven years to reach $1,249m by 2017. The growth will primarily be driven by an increase in the average number of days spent in the hospitals due to inappropriate initial and steady increase in elderly and immuno-suppressed population. At present the market has six approved therapies, out of which Vancomycin and Synercid (Quinupristin+Dalfopristin) are generic and rest four are branded drugs. Currently, the market is dominated by drugs like Vancomycin, Zyvox (linezolid) and Cubicin (daptomycin). As the disease is curable when identified in time, the unmet need seems to be low. Although the existing drugs such as Vancomycin, Zyvox, Cubicin, Tygacil (tygecycline), Vibativ (televancin) and Synercid are capable of curing the disease, still there are unmet needs which can be tapped with the emerging agents which have better safety.

ScopeThe report provides information on the key drivers and challenges of the MRSA market. Its Scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) MRSA market revenues data from 2005 to 2010, forecast for seven years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as Penicillin-binding proteins (PBPs) binders, Transglycosylation and Transpeptidation inhibitor, Pleuromutilin bacterial protein synthesis inhibitor, CYP3A4-specific inhibitors and Membrane lysing action.

- Analysis of the current and future competition in the seven key countries MRSA market. Key market players covered are Takeda Pharmaceutical Company Limited/ Forest Laboratories, Merck & Co., Inc., Astrazeneca PLC, Trius Therapeutics, e-Therapeutics, Nabriva Therapeutics, TrioBiotics Pharma and Basilea Pharma.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the MRSA therapeutics market.

- Analysis of key recent licensing and partnership agreements in MRSA market

Reasons to buyThe report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global MRSA market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global MRSA market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global MRSA market landscape? – Identify, understand and capitalize.

To order this report:: Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
Breaking Medicine News(10 mins):